The DAPA-HF and EMPEROR-Reduced trials were pivotal in demonstrating the cardiovascular benefits of SGLT2 inhibitors in terms of reduced heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status [106,107]. This evidence concerns the gene SLC5A2 and diabetes mellitus.